| Full Name | Megan Manno |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 8 Years |
| Location | 1 Cooper Plz, Camden, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831553072 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 25MB10531800 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cooper University Hospital | Camden, NJ | Hospital |
| Virtua West Jersey Hospitals | Voorhees, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cooper Physician Offices Pa | 2860396611 | 241 |
News Archive
Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the U.S. Food and Drug Administration has approved ILUVIEN for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.
What can a rare genetic childhood disease teach us about cancer? Dr. Ayelet Erez of the Weizmann Institute of Science's Department of Biological Regulation says: "A single-mutation disease can act as a 'lens.' If we find exactly what malfunctions in the sick child, we can zoom in and understand the role of the same gene among the many genetic changes that accompany cancer."
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced the initiation of a Phase 1 clinical study to assess the safety, dosimetry and tolerability of LMI1195, a novel F-18 small molecule tracer for imaging cardiac neuronal function, in healthy subjects, undergoing positron emission tomography (PET) imaging.
› Verified 8 days ago
| Entity Name | Cooper Physician Offices Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154369510 PECOS PAC ID: 2860396611 Enrollment ID: O20031122000067 |
News Archive
Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the U.S. Food and Drug Administration has approved ILUVIEN for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.
What can a rare genetic childhood disease teach us about cancer? Dr. Ayelet Erez of the Weizmann Institute of Science's Department of Biological Regulation says: "A single-mutation disease can act as a 'lens.' If we find exactly what malfunctions in the sick child, we can zoom in and understand the role of the same gene among the many genetic changes that accompany cancer."
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced the initiation of a Phase 1 clinical study to assess the safety, dosimetry and tolerability of LMI1195, a novel F-18 small molecule tracer for imaging cardiac neuronal function, in healthy subjects, undergoing positron emission tomography (PET) imaging.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Megan Manno, DO 1 Federal St # 200, Camden, NJ 08103-1088 Ph: (856) 356-4924 | Megan Manno, DO 1 Cooper Plz, Camden, NJ 08103 Ph: (856) 342-2000 |
News Archive
Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the U.S. Food and Drug Administration has approved ILUVIEN for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.
What can a rare genetic childhood disease teach us about cancer? Dr. Ayelet Erez of the Weizmann Institute of Science's Department of Biological Regulation says: "A single-mutation disease can act as a 'lens.' If we find exactly what malfunctions in the sick child, we can zoom in and understand the role of the same gene among the many genetic changes that accompany cancer."
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced the initiation of a Phase 1 clinical study to assess the safety, dosimetry and tolerability of LMI1195, a novel F-18 small molecule tracer for imaging cardiac neuronal function, in healthy subjects, undergoing positron emission tomography (PET) imaging.
› Verified 8 days ago
Dr. Afaf A. Anter, D.O Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Dorrance 222, Camden, NJ 08103 Phone: 856-342-3150 Fax: 856-968-8418 | |
Dr. James Jingren Liu, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2000 | |
Kalpana Thawani, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1600 Haddon Ave, Camden, NJ 08103 Phone: 856-757-3700 Fax: 856-668-8479 | |
Pratik S Shah, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2000 | |
Dr. Gregory Hilditch, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2000 | |
Okebugwu Kamalu, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2000 | |
Maher Al-safadi, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2000 Fax: 856-968-8418 |